• Home Slider 05
  • Slideshow02
  • Slideshow01

 

Le ultime Notizie dal Mondo AME

I servizi per i soci dell'associazione medici endocrinologi

  • Comunicazioni del Presidente a tutti i soci nelle ricorrenze più importanti dell’anno, e molto altro.

  • La vita della nostra Associazione anno per anno: corsi, convegni, congressi, ecc.

  • Associazioni Pazienti e servizi relativi a fornire le informazioni utili a chi vuole approfondire.

  • Un innovativo strumento di aggiornamento culturale e professionale dedicato a tutti soci AME

  • Formazione a Distanza per ottenere quasi tutti i crediti annuali.

  • Linee Guida tematiche e siti che producono Linee Guida

  • Il "cuore" di quello che l'Associazione mette a disposizione dei propri soci

  • Il programma della prossima scadenza in calendario

  • Elenco ragionato delle normative di frequente utilizzo in ambito clinico e diagnostico.

  • La piattaforma di telemedicina per gestire i tuoi pazienti reali nel tuo ambulatorio virtuale.

Scritti dai nostri soci

  • Introduction to the Italian Association of Clinical Endocrinologists. Endocr Metab Immune Disord Drug Targets 2019, 19(8): 1240-2.
  • Cozzi R, et al. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. Endocr Metab Immune Disord Drug Targets DOI: 10.2174/1871530320666200127103320.
  • Cozzi R, et al. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocr Metab Immune Disord Drug Targets DOI: 10.2174/1871530320666200129113328.
  • Lisco G, et al. Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects. Endocr Metab Immune Disord Drug Targets 2019 Nov 18. doi:10.2174/1871530319666191119112950.
  • Sciannimanico S, et al. Metformin: Up to Date. Endocr Metab Immune Disord Drug Targets 2020, 20(2): 172-81.
  • De Tullio A, et al. A Medullary thyroid cancer with paraganglioma-like pattern diagnosed during pregnancy: A case report and literature revision. Endocr Metab Immune Disord Drug Targets 2020, 20(2): 295-302.
  • Muratori L, et al. Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy Endocr Metab Immune Disord Drug Targets DOI: 10.2174/1871530319666190809144620.
  • Fiore V, et al. Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes. Endocr Metab Immune Disord Drug Targets 2019, 19(5): 571-9.
  • De Pergola G, et al. 25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects. Endocr Metab Immune Disord Drug Targets 2019, 19(6): 838-44.
  • Negro R, Greco G. Unfavorable Outcomes in Solid and Spongiform Thyroid Nodules Treated with Laser Ablation. A 5-Year Follow-up Retrospective Study. Endocr Metab Immune Disord Drug Targets 2019, 19(7): 1041–5.
  • Iovino M, et al. Neuroendocrine Mechanisms Involved in Male Sexual and Emotional Behavior. Endocr Metab Immune Disord Drug Targets 2019, 19(4): 472-80.
  • Triggiani V, et al. Parathyroid Carcinoma Causing Mild Hyperparathyroidism in Neurofibromatosis Type 1: A Case Report and Systematic Review. Endocr Metab Immune Disord Drug Targets 2019, 19(3): 382-8.
  • Vescini F, et al. Mazabraud's Syndrome: A Case Report and Up-To-Date Literature Review. Endocr Metab Immune Disord Drug Targets 2019, 19(6): 885-93.
  • Cipri C, et al. An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature. Endocr Metab Immune Disord Drug Targets 2019, 19(2): 226-9.
  • Giagulli VA, et al, On Behalf Of The Klinefelter Italian Group King. Neuropsychiatric Aspects in Men with Klinefelter Syndrome. Endocr Metab Immune Disord Drug Targets 2019, 19(2): 109-15.
  • Grimaldi F, et al. Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors. Endocr Metab Immune Disord Drug Targets 2018, 18(6): 618-25.
  • Negro R. Thyroid and Assisted Reproduction Technologies: A Brief Clinical Update with Recommendations for Practice. Endocr Metab Immune Disord Drug Targets 2018, 18: 194–200.
  • Marucci S, et al. Anorexia Nervosa and Comorbid Psychopathology. Endocr Metab Immune Disord Drug Targets 2018, 18(4): 316-24.
  • Grimaldi F, et al. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Metab Immune Disord Drug Targets 2018, 18(5): 419–49.
  • Guglielmi R, et al. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients. Endocr Metab Immune Disord Drug Targets 2018, 18(3): 235-20.
  • Giagulli VA, et al. GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis. Endocr Metab Immune Disord Drug Targets 2017, 17(4): 285-96.

 

Reviews del 2019 che segnaliamo

  • Saysho Y, et al. Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. Endocr Metab Immune Disord Drug Targets 2019, 19: 121-7.
  • Gioldasi S, et al. Metabolic Association between Leptin and the Corticotropin Releasing Hormone. Endocr Metab Immune Disord Drug Targets 2019, 19: 458-66.
  • D’Angelo S, et al. BPA and Nutraceuticals, Simultaneous Effects on Endocrine Functions. Endocr Metab Immune Disord Drug Targets 2019, 19: 594-604.
  • De La Cruz JA, et al. The Pleiotropic Effects of Statins in Endocrine Disorders. Endocr Metab Immune Disord Drug Targets 2019, 19: 787-93.
  • Ortega E, et al. Adrenergic Regulation of Macrophage-Mediated Innate/Inflammatory Responses in Obesity and Exercise in this Condition: Role of β2 Adrenergic Receptors. Endocr Metab Immune Disord Drug Targets 2019, 19: 1089-99.
  • Elmadfa E, Meyer Al. The Role of the Status of Selected Micronutrients in Shaping the Immune Function. Endocr Metab Immune Disord Drug Targets 2019, 19: 1100-15.

Iscriviti o rinnova la tua iscrizione ANNUALE

Nuova iscrizione

Nuova iscrizione

Se hai meno di 38 anni
Scopri le condizioni di particolare favore per i giovani che si iscrivono ad AME.

Iscriviti

Nuova iscrizione

Nuova iscrizione

Nuova iscrizione oltre i 38 anni
Tutta la rete di servizi e strumenti di aggiornamento per la propria professione

Iscriviti

Rinnovo iscrizione

Rinnovo iscrizione

Se hai meno di 38 anni
Condizioni di particolare favore per i giovani che rinnovano la quota di iscrizione ad AME

Iscriviti

Rinnovo iscrizione

Rinnovo iscrizione

Rinnovo iscrizione oltre i 38 anni
Uno strumento all'avanguardia per essere sempre aggiornati nella propria professione.

Iscriviti